Robert Haim Belmaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert Haim Belmaker has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Pesach Lichtenberg
The Hebrew University in Jerusalem
25 shared publications Yuly Bersudsky
Senior Lecturer in Psychiatry, Ben Gurion University of the Negev, Israel
4 shared publications- Yuly Bersudsky
Stanley Research Center, Ministry of Health, Beer‐Sheba Mental Health Center, Beer‐Sheva, Israel
4 shared publications G. Agam
Psychiatry Research Unit, Mental Health Center, Ben-Gurion University of the Negev, Beersheba, Israel
3 shared publicationsGalila Agam
Ben-Gurion University of the Negev, Beer-Sheva, Israel
3 shared publicationsJoseph Levine
Beersheva Mental Health Center, Ben Gurion University of the Negev, Beersheva, Israel
3 shared publications
Latest Publications
- Open Access
- 4 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1850
At 75 Years, Is Lithium the Gold Standard in Bipolar Disorder?
Lithium was the first discovered mood stabilizer for bipolar disorder. However, several antiepileptics such as valproate and carbamazepine have also proven to be mood stabilizers in all phases of bipolar disorder with profiles barely distinguishable from lithium. Second-generation antipsychotics were slowly recognized in almost all cases to be useful in all phases of bipolar disorder. These different treatments have not been found to have any common mechanism of action. Indeed, lithium itself has numerous biochemical effects that are often not replicable. The newest biochemical effects described for lithium are exciting but are still merely promising and should not be taught to medical students as facts, especially since they do not explain the fact that several antiepileptic and second-generation antipsychotics also work well in all phases of bipolar disorder. Lithium is not specific to bipolar disorder but has uses in several other psychiatric and nonpsychiatric conditions. Lithium, like most treatments in medicine, is nonspecific; it is still useful in many cases, but is not in any sense a “gold standard”.
- 4 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1850
Open AccessAt 75 Years, Is Lithium the Gold Standard in Bipolar Disorder?
Lithium was the first discovered mood stabilizer for bipolar disorder. However, several antiepileptics such as valproate and carbamazepine have also proven to be mood stabilizers in all phases of bipolar disorder with profiles barely distinguishable from lithium. Second-generation antipsychotics were slowly recognized in almost all cases to be useful in all phases of bipolar disorder. These different treatments have not been found to have any common mechanism of action. Indeed, lithium itself has numerous biochemical effects that are often not replicable. The newest biochemical effects described for lithium are exciting but are still merely promising and should not be taught to medical students as facts, especially since they do not explain the fact that several antiepileptic and second-generation antipsychotics also work well in all phases of bipolar disorder. Lithium is not specific to bipolar disorder but has uses in several other psychiatric and nonpsychiatric conditions. Lithium, like most treatments in medicine, is nonspecific; it is still useful in many cases, but is not in any sense a “gold standard”.
- Open Access
- 7 November 2023
- Published by Wiley in Bipolar Disorders
- Vol. 25 (8) , 700
Letter to editor: Bipolar disorders
- 7 November 2023
- Published by Wiley in Bipolar Disorders
- Vol. 25 (8) , 700
Open AccessLetter to editor: Bipolar disorders
- 19 October 2023
- Published by Springer Nature
- p. 199-200
Pharmacological Treatment of Alcohol Abuse: A Short Chapter
- 19 October 2023
- Published by Springer Nature
- p. 199-200
Pharmacological Treatment of Alcohol Abuse: A Short Chapter
- 19 October 2023
- Published by Springer Nature
- p. 115-121
Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Deep Brain Stimulation and tDCS
- 19 October 2023
- Published by Springer Nature
- p. 115-121
Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Deep Brain Stimulation and tDCS
- 19 October 2023
- Published by Springer Nature
- p. 165-169
Ketamine and Psychedelics in PTSD and Depression: The New Frontier or the New Pandemic?
- 19 October 2023
- Published by Springer Nature
- p. 165-169
Ketamine and Psychedelics in PTSD and Depression: The New Frontier or the New Pandemic?
- 19 October 2023
- Published by Springer Nature
- p. 153-158
Drugs for Obsessive Compulsive Disorder: Could Such Obviously Psychological Disorders Have a Pharmacological Treatment?
- 19 October 2023
- Published by Springer Nature
- p. 153-158
Drugs for Obsessive Compulsive Disorder: Could Such Obviously Psychological Disorders Have a Pharmacological Treatment?
- 19 October 2023
- Published by Springer Nature
- p. 131-141
Stimulant Drugs: Are They Specific for Attention Deficit Disorder or Are They Abused and Overused?
- 19 October 2023
- Published by Springer Nature
- p. 131-141
Stimulant Drugs: Are They Specific for Attention Deficit Disorder or Are They Abused and Overused?
- 19 October 2023
- Published by Springer Nature
- p. 201-204
Is There a Potential for New Treatments in Psychopharmacology or Have We Picked All the Low Hanging Fruit?
- 19 October 2023
- Published by Springer Nature
- p. 201-204
Is There a Potential for New Treatments in Psychopharmacology or Have We Picked All the Low Hanging Fruit?
- 19 October 2023
- Published by Springer Nature
- p. 179-186
Sexual Psychopharmacology: Important Symptomatic Treatment in Depression and Anxiety?
- 19 October 2023
- Published by Springer Nature
- p. 179-186
Sexual Psychopharmacology: Important Symptomatic Treatment in Depression and Anxiety?